Notify me when KKR Genetic Disorder L.P. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | Common Stock, par value $0.001 per share | 7% | $436,020,726 | -$197,280,000 | 13,260,971 | -31% | KKR Genetic Disorder L.P. | 12 May 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|